Della Sala Francesca, Barretta Marco, di Gennaro Mario, Paradiso Rubina, Borriello Giorgia, Borzacchiello Assunta
Institute of Polymers, Composites and Biomaterials, National Research Council (IPCB-CNR), Viale J.F. Kennedy 54, 80125 Naples, Italy.
Department of Environmental, Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania "L. Vanvitelli", 81100 Caserta, Italy.
Gels. 2024 Nov 1;10(11):709. doi: 10.3390/gels10110709.
Pathogen infections constitute a serious problem in the field of lung diseases, especially in severe conditions such as chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS). Exacerbations of COPD and ARDS can be significantly influenced by bacterial infections from Pseudomonas aeruginosa and Staphylococcus aureus, which can hasten the decline of lung function. Moreover, the abuse of high-dose antibiotics used to treat obstinate infections is contributing to the growing issue of multidrug resistance (MDR) by microorganisms. Currently, new therapeutic strategies capable of surprising and fighting pathogens with new modalities are missing. In this framework, bio-composite nanogels (NGs) based on natural polymers with intrinsic antimicrobial properties such as chitosan (CS) and hyaluronic acid (HA) have been developed for the treatment of lung infections. The DLS and TEM results showed that NGs have a spherical shape with a size smaller than 100 nm, making it possible for them to potentially reach the lung site and evade the clearance of alveolar macrophages. FTIR spectra demonstrated that only electrostatic interactions, not chemical reactions, occur between NG precursors. Rheological analysis highlighted NGs' injectability and mucoadhesive capacity. Moreover, an MTT assay on human lung fibroblast cells for biocompatibility evaluation showed good viability up to 48 h. Finally, an antimicrobial test on and showed an increase in antimicrobial activity as the NG concentration increases, with a reduction in bacterial growth of around 60% at 375 μg/mL.
病原体感染是肺部疾病领域的一个严重问题,尤其是在慢性阻塞性肺疾病(COPD)和急性呼吸窘迫综合征(ARDS)等严重病症中。铜绿假单胞菌和金黄色葡萄球菌引起的细菌感染会对COPD和ARDS的病情加重产生显著影响,加速肺功能衰退。此外,用于治疗顽固性感染的高剂量抗生素的滥用,正导致微生物多重耐药(MDR)问题日益严重。目前,缺乏能够以新方式惊人地对抗病原体的新治疗策略。在此框架下,基于具有固有抗菌特性的天然聚合物(如壳聚糖(CS)和透明质酸(HA))的生物复合纳米凝胶(NGs)已被开发用于治疗肺部感染。动态光散射(DLS)和透射电子显微镜(TEM)结果表明,NGs呈球形,尺寸小于100nm,使其有可能到达肺部并逃避肺泡巨噬细胞的清除。傅里叶变换红外光谱(FTIR)表明,NGs前体之间仅发生静电相互作用,而非化学反应。流变学分析突出了NGs的可注射性和粘膜粘附能力。此外,对人肺成纤维细胞进行的MTT试验用于生物相容性评估,结果显示在长达48小时内细胞活力良好。最后,对[具体细菌1]和[具体细菌2]的抗菌测试表明,随着NG浓度的增加,抗菌活性增强,在375μg/mL时细菌生长减少约60%。